» Articles » PMID: 19554571

Initial Testing (stage 1) of Lapatinib by the Pediatric Preclinical Testing Program

Abstract

Background: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer.

Methods: Lapatinib was tested against the cell lines of the PPTP in vitro panel at concentrations ranging from 1.0 nM to 10.0 microM. Lapatinib was tested against the xenografts of the PPTP in vivo panels using a twice-daily oral administration schedule for 6 weeks (5 days on, 2 days off) at a dose of 160 mg/kg (320 mg/kg/day). Lapatinib pharmacokinetic parameters were determined in scid(-/-) mice.

Results: The median IC(50) value for lapatinib against the entire PPTP cell line panel was 6.84 microM (range, 2.08 to >10.0 microM). Lapatinib was well tolerated in vivo, with toxicity in only 1.5% of the treated animals. Lapatinib induced significant differences in EFS distribution compared to controls in 1 of 41 xenografts tested. No objective responses were observed in any of the solid tumor panels or in the ALL panel. Lapatinib systemic exposure was consistent with previously observed values.

Conclusions: Lapatinib has little activity against the xenografts of the PPTP's in vivo panel, and its in vitro activity occurs at concentrations above those associated with specific EGFR/ErbB2 inhibition. These results likely reflect lack of ErbB2 overexpression in the models studied and suggest that adult and pediatric cancers may fundamentally differ in the applicability of EGFR family members as therapeutic targets.

Citing Articles

Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

Candido M, Medeiros M, Veronez L, Bastos D, Oliveira K, Pezuk J Pharmaceutics. 2023; 15(2).

PMID: 36839989 PMC: 9966033. DOI: 10.3390/pharmaceutics15020664.


Engages an Inhibitory Protein Network to Downregulate Expression upon DNA Damage.

Palombo R, Paronetto M Cancers (Basel). 2022; 14(6).

PMID: 35326688 PMC: 8946712. DOI: 10.3390/cancers14061537.


Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

Bandyopadhyay A, Favours E, Phelps D, Pozo V, Ghilu S, Kurmashev D Pediatr Blood Cancer. 2017; 65(2).

PMID: 29080385 PMC: 5739936. DOI: 10.1002/pbc.26870.


A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.

Jones L, Carol H, Evans K, RICHMOND J, Houghton P, Smith M Leukemia. 2016; 30(11):2133-2141.

PMID: 27416986 DOI: 10.1038/leu.2016.192.


The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.

Bid H, Phelps D, Xaio L, Guttridge D, Lin J, London C Mol Cancer Ther. 2016; 15(5):1018-28.

PMID: 26908627 PMC: 4873398. DOI: 10.1158/1535-7163.MCT-15-0567.


References
1.
Hughes D, Thomas D, Giordano T, Baker L, McDonagh K . Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004; 64(6):2047-53. DOI: 10.1158/0008-5472.can-03-3096. View

2.
Dancey J . Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs. 2007; 67(8):1125-38. DOI: 10.2165/00003495-200767080-00003. View

3.
Friedman H, COLVIN O, Skapek S, Ludeman S, ELION G, Schold Jr S . Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res. 1988; 48(15):4189-95. View

4.
Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

5.
Rusnak D, Alligood K, Mullin R, Spehar G, Arenas-Elliott C, Martin A . Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif. 2007; 40(4):580-94. PMC: 6495710. DOI: 10.1111/j.1365-2184.2007.00455.x. View